Your SlideShare is downloading. ×
China cardiovascular system drugs industry market demand forecast and investment strategy planning, 2012 2016
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

China cardiovascular system drugs industry market demand forecast and investment strategy planning, 2012 2016

28
views

Published on

Published in: Business, Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
28
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. China Cardiovascular System Drugs Industry Market Demand Forecast and Investment Strategy Planning, 2012-2016 By Qianzhan Intelligence Website: http://en.qianzhan.com/ Tel:+86 0755 33220413 Email us: carter@qianzhan.com.cn With the improvement of people’s living standard, the acceleration of population aging, and the fast pace of life, people tend to eat more high calorie food and high-fat diet food, which will easily trigger the one of the most serious diseases, named cardiovascular diseases which will threaten our health and life, such as coronary disease, hypertension, and cardiac failure. Moreover, its morbidity and mortality rate rise year after year. Nowadays, the cardiovascular disease has become one of scariest diseases threatening people’s life in the world, whose morbidity and mortality rate jump to the top in the world. Therefore, this field is regarded as one of markets with most development potentials. There is huge demand and prospects for cardiovascular drugs market. However, as to domestic market, a great many of market shares are occupied by leading international pharmaceutical brands or their subsidiaries, so the domestic pharmaceutical corporations need improving their R&D level and market capacity. With Forward’s long-term tracking and collecting market data of cardiovascular system drugs industry, we roundly and accurately analyze the industry structure system for you from the view of mastering the whole industry. This report analyzes the impact of current economic, social and policy environment on the industry; moreover, from aspect of internal industry, it analyzes the market competition situation of cardiovascular pharmaceutical chemicals and traditional Chinese medicines for heart attack, and anti-hypertension in a systematic and specific way. This report will show you the competition situation of whole industry’s market with specific and objective data as well as plenty of evidence. The most distinctive characteristics of this report is forward-looking and timeliness. Based on future development tracks and years’ practice experience of cardiovascular system drugs industry, we conduct objective and profound analysis on overall capacity, market size, competitive landscape and market demand features of China cardiovascular system drugs industry. In addition, based on future development tracks and years’ practice experience of cardiovascular
  • 2. system drugs industry, we conduct prudent analysis and forecast for cardiovascular system drugs industry’s future development trend. This report helps pharmaceutical corporations, R&D institutions, marketing enterprises and investment enterprises to precisely grasp current latest developments of the industry. This report is a first professional report on providing the industry with segment research for cardiovascular drugs and illustrating the competitive landscape from multiple perspectives. Here, we would like to express our sincere gratitude to China Pharmaceutical Profession Association, Ministry of State Information Center, Bureau of Statistics of China, International Information Research Institute, Chinese Academy of International Trade and Economic Cooperation, Tsinghua University Library, Development Research Center of the State Council and Beijing Essence Forward Research Center, for their great support when we conduct this report! Notice: All the market data, especially corporations' ranking data in the report, only for business reference. Please do not take the data for enterprise publicity. Thank you! Or Forward shall not take any responsibility for any consequences! Special tips: Ignoring some subtle hints in the violent change of external environment, and failure of updating strategic decisions timely will finally lead to the loss of competitive advantage. A true successful company will make scientific researches on external environment consciously or unconsciously, so as to formulate a key scientific operating strategy! Best wishes for every enterprise with a big dream that can draw up a high-quality operating decision, to effectively avoid the risks and continuously gain the success. Forward Business Intelligence Co., Ltd. Industry Research Center Research Team of Cardiovascular System Drugs Industry 第 1 章:Overview of China Cardiovascular System Drugs Industry 1.1 Prevalence of Cardiovascular Diseases in China 1.1.1 Cardiovascular Disease and Classification 1.1.2 Patients and Death 1. Total Patients 2. Death Toll 1.1.3 Risks for Cardiovascular Disease 1. High Blood Pressure 2. Smoking
  • 3. 3. Dyslipidemia 4. Others 1.1.4 Medical Treatment for Cardiovascular Disease 1.2 Overview of Cardiovascular System Drugs Industry 1.2.1 Definition of Cardiovascular System Drugs Industry 1.2.2 Research Scope for Cardiovascular System Drugs Industry 1.2.3 Analytical Systems for Cardiovascular System Drugs Industry 第 2 章 : Development Environment for China Cardiovascular System Drugs Industry 2.1 Economic Conditions’ Impact on the Development of Industry 2.1.1 International Macro-economic Environment 1. International Macro-economic Status 2. International Macro-economic Outlook 2.1.2 Domestic Macro-economic Environment 1. Domestic Macro-economic Status 2. Domestic Macro-economic Outlook 2.1.3 Macro-economic Environment’s Impact on the Development of Industry 2.2 Social Considerations’ Impact on the Development of Industry 2.2.1 Social Considerations Associated with Cardiovascular Disease 2.2.2 Social Considerations’ Impact on the Development of Industry 2.3 Policies’ Impact on the Development of Industry 2.3.1 Explanation of Policies Related to Industry Development 2.3.2 Explanation of Regulations Related to Industry Development 2.3.3 Policies’ Impact on the Development of Industry 第 3 章 : Analysis of Market Status of Cardiovascular System Drugs Industry 3.1 Development Overview of International Cardiovascular System Drugs Market 3.1.1 Market Scale 3.1.2 Competitive Landscape 3.1.3 R&A Situation of International Pharmaceutical Corporations in China 3.1.4 Development Trend 3.2 Development Status of Domestic Cardiovascular System Drugs Industry 3.2.1 Market Features 3.2.2 Market Scale 3.2.3 Competitive Landscape in Major Cities 3.2.4 Competition Position for Major Manufacturers 第 4 章 : Analysis of Pharmaceutical Chemicals Competition for Cardiovascular System in China 4.1 Overview of Cardiovascular Pharmaceutical Chemicals Market 4.1.1 Overview of Pharmaceutical Chemicals Market
  • 4. 4.1.2 Size of Pharmaceutical Chemicals Market 4.1.3 Competitive Landscape for Drug Segments 4.1.4 Competitive Landscape for Regional Markets 4.2 Analysis of Cardiac drugs Market 4.2.1 Drugs and Market Overview 4.2.2 Market Size and Change Trend 4.2.3 Competitive Position for Manufacturers 4.2.4 Competitive Landscape for Drugs Market 4.2.5 Analysis of Major Drugs Market 1. Alprostadil 2. Phosphocreatine 3. Coenzyme Complex 4. Isosorbide Dinitrate 4.3 Analysis of Vasodilator Drugs Market 4.3.1 Drugs and Market Overview 4.3.2 Market Size and Change Trend 4.3.3 Competitive Position for Manufacturers 4.3.4 Competitive Landscape for Drugs Market 4.3.5 Analysis of Major Drugs Market 1. Cinepazide 2. Drochloride and Glucose Injection 3. Fasudil 4. 3-n-butylphthalide 5. Ligustrazine 4.4 Analysis of ACE inhibitor Market 4.4.1 Drugs and Market Overview 4.4.2 Market Size and Change Trend 4.4.3 Competitive Position for Manufacturers 4.4.4 Competitive Landscape for Drugs Market 4.4.5 Analysis of Major Drugs Market 1. Valsartan 2. Irbesartan 3. Losartan 4. Telmisartan 5. Benazepril 4.5 Analysis of Calcium Channel Blocker Market 4.5.1 Drugs and Market Overview 4.5.2 Market Size and Change Trend 4.5.3 Competitive Position for Manufacturers 4.5.4 Competitive Landscape for Drugs Market 4.5.5 Analysis of Major Drugs Market 1. Amlodipine 2. Nifedipine 3. Felodipine
  • 5. 4. Amlodipine 5. Nimodipine 4.6 Analysis of Antilipemic Agents Market 4.6.1 Drugs and Market Overview 4.6.2 Market Size and Change Trend 4.6.3 Competitive Position for Manufacturers 4.6.4 Competitive Landscape for Drugs Market 4.6.5 Analysis of Major Drugs Market 1. Atorvastatin 2. Simvastatin 3. Rosuvastatin 4. Pravastatin 4.7 Analysis of Beta Blocking Agent Market 4.7.1 Drugs and Market Overview 4.7.2 Market Size and Change Trend 4.7.3 Competitive Position for Manufacturers 4.7.4 Competitive Landscape for Drugs Market 4.7.5 Analysis of Major Drugs Market 1. Bisoprolol 2. Metoprolol 3. Potassium Magnesium Aspartate 4. Esmolol 5. Arotinolol 4.8 Analysis of Vascular Protective Agents Market 4.8.1 Drugs and Market Overview 4.8.2 Market Size and Change Trend 4.8.3 Competitive Position for Manufacturers 4.8.4 Competitive Landscape for Drugs Market 4.8.5 Analysis of Major Drugs Market 1. Invertose 2. Calcium Dobesilate 3. Diosmin 4. Troxerutin 4.9 Analysis of Antihypertensive Drug Market 4.9.1 Drugs and Market Overview 4.9.2 Market Size and Change Trend 4.9.3 Competitive Position for Manufacturers 4.9.4 Competitive Landscape for Drugs Market 4.9.5 Analysis of Major Drugs Market 1. Urapidil 2. Doxazosin 3. Nitroprusside 4.10 Diuretics 4.10.1 Drugs and Market Overview
  • 6. 4.10.2 Market Size and Change Trend 4.10.3 Competitive Position for Manufacturers 4.10.4 Competitive Landscape for Drugs Market 4.10.5 Analysis of Major Drugs Market 1. Torasemide 2. Indapamide 3. Spironolactone 4. Furosemide 第 5 章:Analysis of Cardiovascular System Drugs Market 5.1 Market Overview of Cardiovascular System Drug 5.2 Competitive Position for Cardiovascular System Drug Manufacturers 5.3 Competitive Landscape of Cardiovascular System Drugs 5.4 Analysis of Major Cardiovascular System Drugs 5.4.1 Ginkgo Injection 1. Brief Introduction to the Drug 2. Competitive Position for Major Manufactures 3. Competitive Landscape for Regional Drugs Market 4. Demand Trend for Drugs Market 5.4.2 Danhong Injection 1. Brief Introduction to the Drug 2. Competitive Position for Major Manufactures 3. Competitive Landscape for Regional Drugs Market 4. Demand Trend for Drugs Market 5.4.3 Danshen Ligustrazine Injection 1. Brief Introduction to the Drug 2. Competitive Position for Major Manufactures 3. Competitive Landscape for Regional Drugs Market 4. Demand Trend for Drugs Market 5.4.4 Ginkgo Biloba Tablet 1. Brief Introduction to the Drug 2. Competitive Position for Major Manufactures 3. Competitive Landscape for Regional Drugs Market 4. Demand Trend for Drugs Market 5.4.5 Carthamus Tinctorius Injection 1. Brief Introduction to the Drug 2. Competitive Position for Major Manufactures 3. Competitive Landscape for Regional Drugs Market 4. Demand Trend for Drugs Market 5.4.6 Shenmai Injection 1. Brief Introduction to the Drug 2. Competitive Position for Major Manufactures 3. Competitive Landscape for Regional Drugs Market 4. Demand Trend for Drugs Market 第 6 章 : Analysis of Leading Corporations in Cardiovascular System
  • 7. Drugs Industry 6.1 Overall Situation of Cardiovascular System Drugs Manufacturers 6.1.1 Comprehensive Overview of Cardiovascular System Drugs Manufacturers 6.1.2 Ranking of Cardiovascular System Drugs Manufacturers by Sales Revenue 6.1.3 Ranking of Cardiovascular System Drugs Manufacturers by Total Profits 6.2 Leading Global Cardiovascular System Drugs Brands’ Investment in China 6.2.1 Pfizer 1. Development Overview 2. Sales Network 3. Product Structure 4. Operation Situation 5. Operation of Pfizer Dalian Plant 6.2.2 Novartis 1. Development Overview 2. Sales Network 3. Product Structure 4. Operation Situation 5. Operation of Beijing Novartis Pharma Ltd. 6.2.3 Merck & Co., Inc. 1. Development Overview 2. Sales Network 3. Product Structure 4. Operation Situation 5. Operation of Hangzhou Moshadong Pharmaceutical Co., Ltd. 6.2.4 Sanofi 1. Development Overview 2. Sales Network 3. Product Structure 4. Operation Situation 5. Operation of Shenzhen Sanofi Pasteur Biological Products Co., Ltd. 6.2.5 Roche Holding Ltd. 1. Development Overview 2. Sales Network 3. Product Structure 4. Operation Situation 5. Operation of Shanghai Roche Pharmaceutical Ltd. 6.2.6 Glaxo Smith Kline 1. Development Overview 2. Sales Network
  • 8. 3. Product Structure 4. Operation Situation 5. Operation of Shanghai Glaxosmithkline Biological Products Co., Ltd. 6.2.7 AstraZeneca 1. Development Overview 2. Sales Network 3. Product Structure 4. Operation Situation 5. Corporate Latest Trend 6.2.8 Bristol-Myers Squibb 1. Development Overview 2. Sales Network 3. Product Structure 4. Operation Situation 5. Operation of Sino-American Shanghai Squibb Pharmaceuticals Ltd. 6.2.9 Boehringer Ingelheim 1. Development Overview 2. Sales Network 3. Product Structure 4. Operation Situation 5. Operation of Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd. 6.3 Case Study of Leading Corporations in Domestic Cardiovascular System Drugs Industry 6.3.1 Beijing SL Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.2 Shenzhen Salubris Pharmaceuticals Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend
  • 9. 6.3.3 Tasly Pharmaceutical Group Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.4 Taiantang Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.5 Guizhou Yibai Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.6 Beijing Tide Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.7 Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A
  • 10. 8. Latest Development Trend 6.3.8 Haikou Qili Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.9 Xi’an Lijun Jinghua Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.10 Nanjing Hicin Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.11 Zhejiang Chengyi Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.12 Beijing Four Rings Bio-pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness
  • 11. 7. Investment M&A 8. Latest Development Trend 6.3.13 Sichuan US-le-Grand Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.14 Yangtze River Pharmaceutical Group 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.15 Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.16 Qilu Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.17 Zhejiang Hisun Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market
  • 12. 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.18 Shandong Buchang Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.19 Shijiazhuang Yiling Pharmaceutical Co., Ltd. 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 6.3.20 China Shineway Pharmaceutical Group Limited 1. Overall Development Information 2. Product and Market Positioning 3. Regional Market Distribution 4. Cardiovascular Drugs Market 5. Overall Operation 6. Operational Strengths and Weakness 7. Investment M&A 8. Latest Development Trend 第 7 章 : Analysis of Development Trend and Prospects for China Cardiovascular System Drugs Industry 7.1 Overall Competition of Industry 7.2 Competition Background of Industry – Both Opportunity and Challenge 7.2.1 Development Opportunity for Industry 1. Relevant Polices Stimulates the Development of Industry 2. Market Cognition 7.2.2 Challenge Confronted by Industry Development 1. Overall Innovation Level of Industry 2. Corporate Size and Competition Strategy for Industry 3. Gap between Market Regulations and International Regulations 4. Staff Training and Technology Transfer Model
  • 13. 7.3 Competition Situation among the Industry – by Fierce 7.3.1 New Entrants 7.3.2 Fierce Internal Competition 7.3.3 Substitute Risk 7.3.4 Bargaining Power of Supplier and Buyer 7.4 Prospects and Forecast for Industry 7.4.1 Development Prospects 7.4.2 Development Trend 7.4.3 Investment Suggestion